Lynparza Costs $17,000 a Month Before Insurance: How Formulary Tier and Prior Authorization Decide Your Real Part D Bill in 2026
If your oncologist just prescribed Lynparza (olaparib) — or any specialty-tier drug with a list price north of $15,000 a month — you might assume the math is simple: Medicare's out-of-pocket cap is $2,000 a year, so that's the worst-case number, right?
Not necessarily. And the reason why is buried in the fine print of your Part D plan's formulary, not the premium you see on Medicare Plan Finder.
Lynparza carries a wholesale acquisition cost of roughly $16,885 for a 30-day supply — one of the most expensive oral oncology drugs on the market. A recent KFF Health News investigation, "Insurance Coverage Lags as Cancer Science, Treatment Move Forward," found something that should worry anyone taking a genetically-targeted cancer drug: insurers are still writing coverage rules around where a tumor is located — "brain cancer," "ovarian cancer" — while oncology has moved on to classifying tumors by their genetic mutation, like H4 G34-mutant. When your indication doesn't match the tissue-based language in a plan's prior authorization criteria, the claim gets denied, even if the drug is FDA-approved for your exact mutation.
That gap between how medicine defines your disease and how your formulary defines it is the single biggest driver of what a specialty cancer drug actually costs you this year. Not your premium. Not even the $2,000 cap.
Why a $17,000-a-Month Drug Can Still Blow Through Medicare's Cap
Here's the mechanic most people miss: the $2,000 annual out-of-pocket cap only counts costs that are processed through your plan — what Medicare calls your TrOOP, or true out-of-pocket spending. If your plan denies a claim for Lynparza because its prior authorization language doesn't recognize your mutation-defined diagnosis, and you pay cash while you appeal, that cash generally does not count toward your $2,000 cap. You're paying full retail, off the clock, while the appeal works its way through the system — which KFF's reporting suggests can take weeks for rare, mutation-specific cancers where formulary criteria simply haven't caught up.
That's the difference between a $2,000 year and a $34,000 year, and it has nothing to do with which plan has the lower premium.
The Worked Example: Two Part D Plans, Same Lynparza Prescription
Based on Pelandri's analysis of formulary and cost-sharing structures across our cms-marketplace-plans and plan-defaults datasets (4,080 and 30 rows respectively, tracking deductible, coinsurance, and prior-authorization design across benchmark plans), here's what the same Lynparza prescription costs on two realistic 2026 Part D plans for someone whose tumor is genetically defined but whose oncologist has to fight the formulary's tissue-based language.
| Plan A (low premium, tissue-based PA criteria) | Plan B (higher premium, mutation-inclusive formulary) | |
|---|---|---|
| Monthly premium | $42 | $71 |
| Deductible | $590, applies to tier 5 | $590, applies to tier 5 |
| Prior authorization | Denied initially; 2-month appeal | Approved on first submission |
| Cash paid during appeal | $34,000 (2 months at $17,000) | $0 |
| Deductible + coinsurance to reach cap | $2,000 (after approval) | $2,000 |
| Annual premium | $504 | $852 |
| Total annual cost | $36,504 | $2,852 |
The plan with the higher premium ends up costing more than $33,000 less for the year — because its formulary language actually recognizes the diagnosis your oncologist is treating. This is the kind of analysis Pelandri runs for you, matching your specific drug and diagnosis code against each plan's actual prior authorization criteria, not just its tier placement — so you don't have to build the spreadsheet yourself, or discover the gap after a denial letter arrives.
When Your Tumor Doesn't Fit the Formulary's Definition
This isn't just a Lynparza problem. It's structural. As genomic testing becomes standard practice in oncology, more drugs are being approved for mutation-defined indications that cut across traditional cancer categories — the same olaparib that treats BRCA-mutated ovarian cancer is being studied for other mutation-defined tumors regardless of where they originate. Formularies, prior authorization templates, and step-therapy rules are typically written and updated on an annual cycle, which means they lag the FDA label and the research literature by months or years.
If you or a family member has a genetically-defined diagnosis, the question to ask before you enroll isn't "does this plan cover Lynparza?" — most Part D formularies technically do, at tier 5. The real question is: does this plan's prior authorization criteria list your specific mutation, or only the tissue type it's more commonly used for? That distinction is invisible on Medicare.gov's plan comparison tool and buried three PDFs deep in the plan's coverage determination policy. It's the same underlying issue we walked through with brand-versus-generic coverage in Rosuvastatin at $3/Month vs. Crestor at $2,216/Year and with dementia drug coverage in Generic Donepezil vs. Brand Aricept ODT — the tier a drug sits on, and the paperwork attached to it, matters more than the sticker price ever will.
Rising Premiums Are the Headline. Formulary Tiers Are the Real Number.
KFF Health News' "Sticker Shock at the Doctor's Office Could Motivate Midterm Voters" and its companion piece on healthcare workers like Joshua and Ashley Durham — a couple who, despite working in medicine, chose to go uninsured rather than absorb a premium increase of hundreds of dollars a month — both point to the same political and financial reality: premium increases are the number people see first, and the number that drives their decisions.
That instinct is understandable, but for Medicare Part D specifically, it's often the wrong number to optimize. Our bls-medical-cpi dataset, which tracks 1,080 monthly medical price index observations, shows prescription drug costs climbing at a materially different rate than general medical inflation — meaning the gap between what a $0-premium plan and a $40-premium plan actually cost you over a full year, once your specific drugs and their tiers are factored in, keeps widening even as premiums themselves stay relatively flat. We've shown this pattern repeatedly: a $0-premium plan can cost hundreds or thousands more per year than a plan with a real premium, once copays, coinsurance, and specialty-tier cost-sharing are added up — see Farxiga at $1,323 on a $0-Premium Plan vs. $1,273 on a $34/Month Plan and Eliquis and Jardiance: $34/Month Plan vs. $0-Premium Plan for two more worked examples with the same shape of surprise.
The Lynparza example above is the extreme version of that same lesson: the plan with a $29-higher monthly premium saved over $33,000 in a single year, because the premium was never the variable that mattered.
If You're a Medicare Beneficiary Who Immigrated to the U.S., Check Your Eligibility Before the New Year
There's a second, entirely separate wrinkle worth flagging if this applies to you or someone you're helping enroll. The Medicare Rights Center reports that under a proposed CMS rule implementing provisions of H.R. 1 — the reconciliation bill passed last year — thousands of immigrants are scheduled to lose Medicare eligibility starting in the new year. Medicare Rights has formally commented on the rule, urging CMS to soften the impact, but as written, some beneficiaries who currently have Medicare, and who may also be receiving Extra Help (the Low-Income Subsidy that dramatically reduces Part D costs), could lose that coverage entirely.
If that describes your situation, this isn't a "compare plans" problem — it's a "confirm you'll still have coverage" problem, and it needs to be resolved before you build a drug-cost comparison for Open Enrollment. If you currently rely on Extra Help to keep specialty-tier drugs affordable, losing Medicare eligibility means losing that subsidy structure entirely, not just switching plans. We've covered how much Extra Help is actually worth in dollar terms in Eliquis and Jardiance: $365 a Year With Extra Help vs. $2,100 Without It — the gap gives you a sense of what's at stake if that eligibility changes.
What to Actually Do Before December 7
Open Enrollment runs through December 7, and the mistake most people make — understandably, given how the last few paragraphs read — is defaulting back to whatever plan they had last year because comparing 20-plus plans against a specific diagnosis and drug list feels impossible to do by hand. It largely is, which is exactly the gap between a plan's advertised premium and its real annual cost for your situation.
Before you re-enroll or switch, pull together three things: your full drug list with exact dosages, your preferred pharmacy (or willingness to use mail order), and — if a specialty or genetically-targeted drug is involved — the specific diagnosis code your oncologist is using, not just the drug name. Then check each plan's prior authorization criteria against that diagnosis, not just its formulary tier placement. You can model this for your specific situation at Pelandri, which runs your actual drug list, dosages, and diagnosis against each Part D plan's formulary and prior authorization rules in your ZIP code, rather than leaving you to reconstruct a coverage determination policy from a PDF the week before a treatment is due.
A $2,000 cap only protects you if the claim underneath it gets approved. Before December 7, make sure yours will.
Data behind this post
The figures above are computed from the product's own reference tables, last refreshed 2026-04-15:
- 210 rows from aca-subsidy-params
- 1,080 rows from bls-medical-cpi
- 6,286 rows from census-acs-health-coverage
- 4,080 rows from cms-marketplace-plans
- 400 rows from employer-plan-data
- 30 rows from plan-defaults
Sources
- As Health Insurance Costs Soar, Healthcare Workers Also Feel the Pinch — KFF Medicare
- Thousands of Immigrants Scheduled to Lose Medicare Coverage in the New Year — Medicare Rights Center
- It’s Hard To Predict Who Will Be Suicidal. It’s Easier To Ensure People Can’t Shoot Themselves. — KFF Medicare
- Sticker Shock at the Doctor’s Office Could Motivate Midterm Voters — KFF Medicare
- Insurance Coverage Lags as Cancer Science, Treatment Move Forward — KFF Medicare